Switch to:
» Details

Insider Trades

Latest Guru Trades with CCEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621999    SIC: 8099
Compare:OTCPK:FCHS, AMEX:AMS, AMEX:SSY, OTCPK:CVHIF, OTCPK:BICX, OTCPK:QNIIF, OTCPK:PFHO, AMEX:HH, OTCPK:SPIN, OTCPK:WNDM, OTCPK:AMEH, OTCPK:GRST, OTCPK:USNU, OTCPK:MIHI, OTCPK:GNOW, OTCPK:CATS, AMEX:HLTH, NYSE:AAC, NAS:BIOS, NYSE:CCM » details
Cryo-Cell International Inc is engaged in cellular processing & cryogenic storage. Its services include umbilical cord blood banking, umbilical cord tissue banking and umbilical cord blood & tissue banking prices.

Cryo-Cell International, Inc. was incorporated on September 11, 1989 in the State of Delaware. The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord9(r)) blood stem cells for family use. The Company has established private family cord blood stem cell banks in terms of the number of specimens preserved. Its headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations, including the processing and storage of specimens. The specimens are stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Oldsmar, Florida. It has expanded its research and development activities to develop technologies related to stem cells other than umbilical cord blood stem cells. During 2006, in parallel with its R&D associated with placental stem cells, the Company discovered novel technology related to menstrual stem cells. In November 2007, the Company announced the launch of its C'elleSM service related to this patent-pending technology, and the Company continues to focus its current research and development activities mainly on the C'elle service and related new menstrual stem cell technologies. The Company is actively marketing the C'elle service both through a bundled offer with the Company's U-Cord service and on a stand-alone basis. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, Lamaze instructors and other childbirth educators, certified nurse-midwives and other related healthcare professionals. To increase awareness among expectant parent audiences, the Company continues to promote its service in several national targeted prenatal magazines including American Baby and Fit Pregnancy, as well as several magazines distributed during childbirth classes. Expectant parents have also received information via emails and the Company has increased its internet marketing campaigns. Its competitors are Cord Blood Registry, Inc., ViaCord, a division of ViaCell, Inc., a wholly-owned subsidiary of PerkinElmer and LifeBankUSA, a division of Celgene. The Company is required to register with the FDA under the Public Health Service Act.

Ratios

vs
industry
vs
history
PS Ratio 1.67
CCEL's PS Ratio is ranked lower than
53% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 1.67 vs. CCEL: 1.67 )
Ranked among companies with meaningful PS Ratio only.
CCEL' s PS Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.34 Max: 2.92
Current: 1.67
0.28
2.92
Price-to-Free-Cash-Flow 9.65
CCEL's Price-to-Free-Cash-Flow is ranked higher than
87% of the 115 Companies
in the Global Medical Care industry.

( Industry Median: 23.76 vs. CCEL: 9.65 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CCEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.05  Med: 13.61 Max: 218.46
Current: 9.65
4.05
218.46
Price-to-Operating-Cash-Flow 8.92
CCEL's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 168 Companies
in the Global Medical Care industry.

( Industry Median: 14.75 vs. CCEL: 8.92 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CCEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.33  Med: 11.81 Max: 277
Current: 8.92
3.33
277
Current Ratio 0.82
CCEL's Current Ratio is ranked lower than
78% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.29 vs. CCEL: 0.82 )
Ranked among companies with meaningful Current Ratio only.
CCEL' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.38 Max: 35.3
Current: 0.82
0.47
35.3
Quick Ratio 0.78
CCEL's Quick Ratio is ranked lower than
75% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. CCEL: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
CCEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.38 Max: 35.3
Current: 0.78
0.47
35.3
Days Inventory 30.01
CCEL's Days Inventory is ranked lower than
63% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 16.39 vs. CCEL: 30.01 )
Ranked among companies with meaningful Days Inventory only.
CCEL' s Days Inventory Range Over the Past 10 Years
Min: 2.07  Med: 9.79 Max: 30.01
Current: 30.01
2.07
30.01
Days Sales Outstanding 69.36
CCEL's Days Sales Outstanding is ranked lower than
79% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. CCEL: 69.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.79  Med: 51.88 Max: 73.85
Current: 69.36
25.79
73.85
Days Payable 100.97
CCEL's Days Payable is ranked higher than
74% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 39.14 vs. CCEL: 100.97 )
Ranked among companies with meaningful Days Payable only.
CCEL' s Days Payable Range Over the Past 10 Years
Min: 49.91  Med: 82.68 Max: 104.76
Current: 100.97
49.91
104.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 6.60
CCEL's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. CCEL: 6.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -0.4 Max: 6.6
Current: 6.6
-14.9
6.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.24
CCEL's Price-to-Median-PS-Value is ranked lower than
72% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. CCEL: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CCEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.26 Max: 67.6
Current: 1.24
0.29
67.6
Earnings Yield (Greenblatt) % -5.96
CCEL's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. CCEL: -5.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CCEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.96  Med: 9.3 Max: 642.2
Current: -5.96
-5.96
642.2

More Statistics

Revenue (TTM) (Mil) $23.06
EPS (TTM) $ -0.30
Beta-0.15
Short Percentage of Float0.05%
52-Week Range $2.81 - 5.00
Shares Outstanding (Mil)6.80
» More Articles for CCEL

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Nov 03 2016
CRYO CELL INTERNATIONAL INC Financials Oct 21 2016
Cryo-Cell International, Inc. :CCEL-US: Earnings Analysis: Q3, 2016 By the Numbers : October 19,... Oct 19 2016
CRYO CELL INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Oct 17 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 13 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 30 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 01 2016
Cryo-Cell International, Inc. :CCEL-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016 Jul 26 2016
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against... Jul 19 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 12 2016
CRYO CELL INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Jul 11 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 07 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events Jul 01 2016
SHAREHOLDER ALERT: Lundin Law PC Announces Ongoing Investigation Of Cryo-Cell International, Inc.... Jun 29 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Violations of... Jun 29 2016
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Cryo-Cell International, Inc.... Jun 28 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 24 2016
Cryo-Cell International, Inc. :CCEL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 Jun 22 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... May 26 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into... May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK